Semaglutide and tirzepatide for obesity: Effectiveness and valuedraft evidence report
We have a term for this when the bodys immune response goes into overdrive, cytokine storm, which is an uncontrolled inflammatory response from the immune system that overwhelms our bodys ability to compensate, and it contributes to why some people can rapidly die from certain infections or illnesses
Orlistat, phentermine/topiramate, naltrexone/bupropion, and the incretin-based drugs liraglutide and semaglutide, both GLP-1 receptor agonists (GLP-1RA), and tirzepatide, a biased dual GIP/GLP-1 receptor agonist, are currently both FDA and EMA approved for the management of non-syndromic obesity 10
Additionally, KPV suppresses the excessive inflammatory signaling that delays chronic wound healing in diabetic and aged tissue models
A: Retatrutide is a triple agonist peptide that targets GLP-1, GIP, and glucagon receptors to support metabolic function and weight regulation